Cancer-associated TP53 mutants can have the capability of abrogating WT TP53-induced transactivation, which is called “dominant-negative potential”, since the p53 heterotetramer consisting of the WT TP53 dimer and TP53 mutant dimer is generated in tumor cells harboring the TP53 mutation and WT TP53 as heterozygotes [21]. Here, TP53 is linked to cancer.